Pemafibrate (BioDeep_00000837755)
代谢物信息卡片
Pemafibrate
化学式: C28H30N2O6 (490.2104)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC(C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3
InChI: InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
Pemafibrate is a highly selective PPARα agonist, with an EC50 of 1 nM.
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D10711
- PubChem: 11526038
- DrugBank: DB15212
- ChEMBL: CHEMBL247951
- CAS: 848259-27-8
- medchemexpress: HY-17618
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Akihiro Nakamura, Yuta Kagaya, Hiroki Saito, Masanori Kanazawa, Kenjiro Sato, Masanobu Miura, Masateru Kondo, Hideaki Endo. Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome.
Heart and vessels.
2024 Jun; 39(6):486-495. doi:
10.1007/s00380-024-02363-z. [PMID: 38393377] - Rimi Izumihara, Hiroshi Nomoto, Kenichi Kito, Yuki Yamauchi, Kazuno Omori, Yui Shibayama, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease.
Diabetes & metabolism journal.
2024 May; 48(3):473-481. doi:
10.4093/dmj.2023.0370. [PMID: 38419467] - Tsutomu Hirano, Toshiyuki Hayashi, Hiroe Sugita, Atsuko Tamasawa, Satoshi Goto, Masako Tomoyasu, Takeshi Yamamoto, Makoto Ohara, Michishige Terasaki, Hideki Kushima, Yasuki Ito, Sho-Ichi Yamagishi, Yusaku Mori. Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.
Journal of diabetes investigation.
2023 Dec; 14(12):1401-1411. doi:
10.1111/jdi.14076. [PMID: 37647503] - Muhammad Shayan Khan, Ghulam Mujtaba Ghumman, Abdul Baqi, Jay Shah, Muhammad Aziz, Tanveer Mir, Ayesha Tahir, Srinivas Katragadda, Hemindermeet Singh, Mohammed Taleb, Syed Sohail Ali. Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2023 Jul; ?(?):. doi:
10.1007/s40256-023-00593-6. [PMID: 37524955] - Yukino Katakura, Masashi Shimoda, Mana Ohnishi, Takashi Kusano, Kazunori Dan, Hayato Isobe, Ryo Wamata, Yuichiro Iwamoto, Yoshiro Fushimi, Junpei Sanada, Atsushi Obata, Tomohiko Kimura, Fuminori Tatsumi, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Nutrition, metabolism, and cardiovascular diseases : NMCD.
2023 Jul; 33(7):1444-1452. doi:
10.1016/j.numecd.2023.02.011. [PMID: 37246074] - Masako Iwasaki, Hitoshi Suzuki, Yukako Umezawa, Takeo Koshida, Midori Saito, Hiromitsu Fukuda, Hisatsugu Takahara, Keiichi Matsuzaki, Yusuke Suzuki. Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Medicine.
2023 Feb; 102(7):e32818. doi:
10.1097/md.0000000000032818. [PMID: 36800602] - Aruna Das Pradhan, Robert J Glynn, Jean-Charles Fruchart, Jean G MacFadyen, Elaine S Zaharris, Brendan M Everett, Stuart E Campbell, Ryu Oshima, Pierre Amarenco, Dirk J Blom, Eliot A Brinton, Robert H Eckel, Marshall B Elam, João S Felicio, Henry N Ginsberg, Assen Goudev, Shun Ishibashi, Jacob Joseph, Tatsuhiko Kodama, Wolfgang Koenig, Lawrence A Leiter, Alberto J Lorenzatti, Boris Mankovsky, Nikolaus Marx, Børge G Nordestgaard, Dénes Páll, Kausik K Ray, Raul D Santos, Handrean Soran, Andrey Susekov, Michal Tendera, Koutaro Yokote, Nina P Paynter, Julie E Buring, Peter Libby, Paul M Ridker. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
The New England journal of medicine.
2022 Nov; 387(21):1923-1934. doi:
10.1056/nejmoa2210645. [PMID: 36342113] - Kenichi Kito, Hiroshi Nomoto, Ichiro Sakuma, Akinobu Nakamura, Kyu Yong Cho, Hiraku Kameda, Aika Miya, Kazuno Omori, Shingo Yanagiya, Takahisa Handa, Shinji Taneda, Jun Takeuchi, So Nagai, Kumiko Yamashita, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyoshi. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
Diabetes research and clinical practice.
2022 Oct; 192(?):110091. doi:
10.1016/j.diabres.2022.110091. [PMID: 36174777] - Akihiro Nakamura, Yuta Kagaya, Hiroki Saito, Masanori Kanazawa, Kenjiro Sato, Masanobu Miura, Masateru Kondo, Hideaki Endo. Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
Journal of atherosclerosis and thrombosis.
2022 Jun; ?(?):. doi:
10.5551/jat.63659. [PMID: 35768226] - Henry N Ginsberg, Neil J Hounslow, Yusuke Senko, Hideki Suganami, Pawel Bogdanski, Richard Ceska, Akos Kalina, Roman A Libis, Tatiana V Supryadkina, G Kees Hovingh. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Diabetes care.
2022 04; 45(4):898-908. doi:
10.2337/dc21-1288. [PMID: 35238894] - Atsushi Kimura, Kenya Kamimura, Marina Ohkoshi-Yamada, Yoko Shinagawa-Kobayashi, Ryo Goto, Takashi Owaki, Chiyumi Oda, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model.
Biochemical and biophysical research communications.
2022 03; 596(?):76-82. doi:
10.1016/j.bbrc.2022.01.086. [PMID: 35121372] - Kentaro Murakami, Yusuke Sasaki, Masato Asahiyama, Wataru Yano, Toshiaki Takizawa, Wakana Kamiya, Yoshihiro Matsumura, Motonobu Anai, Tsuyoshi Osawa, Jean-Charles Fruchart, Jamila Fruchart-Najib, Hiroyuki Aburatani, Juro Sakai, Tatsuhiko Kodama, Toshiya Tanaka. Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.
Cells.
2022 02; 11(4):. doi:
10.3390/cells11040720. [PMID: 35203369] - Tatsuya Fujikawa, Yuka Sogabe. Lipid Metabolic Disorder with Varied Clinical Manifestations.
The American journal of medicine.
2022 02; 135(2):e42-e43. doi:
10.1016/j.amjmed.2021.09.011. [PMID: 34655537] - Masao Takahashi, Nobuhiro Ooba, Marina Nagamura, Makoto Ushida, Eiji Kawakami, Masaomi Kimura, Tsugumichi Sato, Yoshinori Takahashi, Junichi Tokuyoshi, Hajime Hashiba, Miwako Kamei, Choichiro Miyazaki, Mitsuaki Shimada. Event Monitoring and Evaluation by Community Pharmacists in Japan: A Pilot Study on Fenofibrate and Pemafibrate.
Current drug safety.
2022; 17(4):350-356. doi:
10.2174/1574886317666220224142511. [PMID: 35209830] - Kumiko Suto, Daiju Fukuda, Masakazu Shinohara, Byambasuren Ganbaatar, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Ken-Ichi Hirata, Masataka Sata. Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice.
Journal of atherosclerosis and thrombosis.
2021 Dec; 28(12):1349-1360. doi:
10.5551/jat.61101. [PMID: 33775978] - Yuji Tanaka, Toshinori Kamisako. Regulation of the expression of cholesterol transporters by lipid-lowering drugs ezetimibe and pemafibrate in rat liver and intestine.
Biochimica et biophysica acta. Molecular basis of disease.
2021 11; 1867(11):166215. doi:
10.1016/j.bbadis.2021.166215. [PMID: 34265370] - Atsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, Kento Imajo, Nobuharu Tamaki, Hideki Suganami, Toshiaki Nojima, Ryohei Tanigawa, Masakazu Iizuka, Yuki Iida, Rohit Loomba. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Alimentary pharmacology & therapeutics.
2021 11; 54(10):1263-1277. doi:
10.1111/apt.16596. [PMID: 34528723] - Kazufumi Dohmen, Shin-Ya Onohara, Shigeru Harada. Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis.
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
2021 10; 78(4):227-234. doi:
10.4166/kjg.2021.092. [PMID: 34697277] - Shizuya Yamashita, Mitsuyo Okazaki, Takeshi Okada, Daisaku Masuda, Koutaro Yokote, Hidenori Arai, Eiichi Araki, Shun Ishibashi. Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
Journal of atherosclerosis and thrombosis.
2021 Sep; 28(9):974-996. doi:
10.5551/jat.60764. [PMID: 33536398] - Toshinori Komatsu, Takashi Miura, Kensuke Joko, Daisuke Sunohara, Tomoaki Mochidome, Toshio Kasai, Uichi Ikeda. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
Internal medicine (Tokyo, Japan).
2021 Sep; 60(17):2741-2748. doi:
10.2169/internalmedicine.6871-20. [PMID: 33776008] - Deokho Lee, Yohei Tomita, Heonuk Jeong, Yukihiro Miwa, Kazuo Tsubota, Kazuno Negishi, Toshihide Kurihara. Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion.
International journal of molecular sciences.
2021 Aug; 22(17):. doi:
10.3390/ijms22179408. [PMID: 34502311] - Naoki Tanaka, Kazutaka Mukaiyama, Akio Morikawa, Satoshi Kawakami, Yasuyuki Ichise, Takefumi Kimura, Akira Horiuchi. Pemafibrate, a novel selective PPARα modulator, attenuates tamoxifen-induced fatty liver disease.
Clinical journal of gastroenterology.
2021 Jun; 14(3):846-851. doi:
10.1007/s12328-021-01386-7. [PMID: 33751406] - Joost Boeckmans, Alessandra Natale, Matthias Rombaut, Karolien Buyl, Brent Cami, Veerle De Boe, Anja Heymans, Vera Rogiers, Joery De Kock, Tamara Vanhaecke, Robim M Rodrigues. Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.
Cell biology and toxicology.
2021 04; 37(2):293-311. doi:
10.1007/s10565-020-09544-2. [PMID: 32613381] - Ichiro Komiya, Akira Yamamoto, Suguru Sunakawa, Tamio Wakugami. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
Lipids in health and disease.
2021 Feb; 20(1):17. doi:
10.1186/s12944-021-01434-8. [PMID: 33610176] - Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib, Tatsuhiko Kodama. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?.
Current atherosclerosis reports.
2021 01; 23(1):3. doi:
10.1007/s11883-020-00897-x. [PMID: 33392801] - Masataka Kusunoki, Takahiko Sakazaki, Kazuhiko Tsutsumi, Tetsuro Miyata, Yoshiharu Oshida. The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors.
Endocrine, metabolic & immune disorders drug targets.
2021; 21(5):919-924. doi:
10.2174/1871530320999200818135553. [PMID: 32819242] - Shin-Ichiro Ogawa, Makiko Shimizu, Hiroshi Yamazaki. Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations.
Xenobiotica; the fate of foreign compounds in biological systems.
2020 Dec; 50(12):1413-1422. doi:
10.1080/00498254.2020.1793030. [PMID: 32628085] - Chie Iitake, Daisaku Masuda, Masahiro Koseki, Shizuya Yamashita. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Cardiovascular diabetology.
2020 11; 19(1):201. doi:
10.1186/s12933-020-01172-8. [PMID: 33246467] - Takuya Minamizuka, Junji Kobayashi, Hayato Tada, Kazuya Miyashita, Masaya Koshizaka, Yoshiro Maezawa, Hiraku Ono, Koutaro Yokote. Detailed analysis of lipolytic enzymes in a Japanese woman of familial lipoprotein lipase deficiency - Effects of pemafibrate treatment.
Clinica chimica acta; international journal of clinical chemistry.
2020 Nov; 510(?):216-219. doi:
10.1016/j.cca.2020.07.031. [PMID: 32682802] - Masatoki Yoshida, Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Megumi Kondo, Kaoru Akazawa, Tomonari Kimura, Hiroaki Ohtsuka, Yuko Ohno, Daiji Miura, Hiroshi Ito. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.
Cardiovascular diabetology.
2020 09; 19(1):149. doi:
10.1186/s12933-020-01132-2. [PMID: 32979918] - Shin-Ichiro Ogawa, Makiko Shimizu, Hiroshi Yamazaki. Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment.
Xenobiotica; the fate of foreign compounds in biological systems.
2020 Sep; 50(9):1023-1031. doi:
10.1080/00498254.2019.1709133. [PMID: 31900032] - Yohei Tomita, Deokho Lee, Yukihiro Miwa, Xiaoyan Jiang, Masayuki Ohta, Kazuo Tsubota, Toshihide Kurihara. Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy.
International journal of molecular sciences.
2020 Aug; 21(17):. doi:
10.3390/ijms21176243. [PMID: 32872333] - Shin-Ichiro Ogawa, Makiko Shimizu, Yusuke Kamiya, Shotaro Uehara, Hiroshi Suemizu, Hiroshi Yamazaki. Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1.
Drug metabolism and pharmacokinetics.
2020 Aug; 35(4):354-360. doi:
10.1016/j.dmpk.2020.03.005. [PMID: 32601018] - Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?.
Current atherosclerosis reports.
2020 07; 22(8):43. doi:
10.1007/s11883-020-00860-w. [PMID: 32671476] - Yu Yang, Yu Zhao, Wenzhen Li, Yuyao Wu, Xin Wang, Yijie Wang, Tingmei Liu, Tinghong Ye, Yongmei Xie, Zhiqiang Cheng, Jun He, Peng Bai, Yiwen Zhang, Liang Ouyang. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
European journal of medicinal chemistry.
2020 Jul; 197(?):112311. doi:
10.1016/j.ejmech.2020.112311. [PMID: 32339855] - Shin-Ichiro Ogawa, Shotaro Uehara, Yoshihiko Tsunenari, Hiroyuki Kawai, Hiroshi Suemizu, Hiroshi Yamazaki. Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver.
Xenobiotica; the fate of foreign compounds in biological systems.
2020 Jul; 50(7):769-775. doi:
10.1080/00498254.2019.1694198. [PMID: 31766940] - Yusuke Sasaki, Masato Asahiyama, Toshiya Tanaka, Shogo Yamamoto, Kentaro Murakami, Wakana Kamiya, Yoshihiro Matsumura, Tsuyoshi Osawa, Motonobu Anai, Jean-Charles Fruchart, Hiroyuki Aburatani, Juro Sakai, Tatsuhiko Kodama. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.
Scientific reports.
2020 05; 10(1):7818. doi:
10.1038/s41598-020-64902-8. [PMID: 32385406] - Atsushi Tanaka, Tsukasa Nakamura, Eiichi Sato, Atsuko Chihara, Koichi Node. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
CEN case reports.
2020 05; 9(2):141-146. doi:
10.1007/s13730-020-00444-2. [PMID: 31950425] - Shinji Kobuchi, Atsushi Shigemura, Yukako Ito, Toshiyuki Sakaeda. A validated LC-MS/MS method for the low-level determination of pemafibrate, a novel SPPARMα, in plasma.
Bioanalysis.
2020 May; 12(10):683-692. doi:
10.4155/bio-2020-0081. [PMID: 32489112] - Kento Ogawa, Takashi Yagi, Tingting Guo, Katsushi Takeda, Hideomi Ohguchi, Hiroyuki Koyama, Daisuke Aotani, Kenro Imaeda, Hiromi Kataoka, Tomohiro Tanaka. Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways.
Biochemical and biophysical research communications.
2020 04; 524(2):385-391. doi:
10.1016/j.bbrc.2020.01.118. [PMID: 32005522] - Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Current atherosclerosis reports.
2020 01; 22(1):5. doi:
10.1007/s11883-020-0823-5. [PMID: 31974794] - Hiroshi Kawanishi, Koji Ohashi, Hayato Ogawa, Naoya Otaka, Tomonobu Takikawa, Lixin Fang, Yuta Ozaki, Mikito Takefuji, Toyoaki Murohara, Noriyuki Ouchi. A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms.
PloS one.
2020; 15(6):e0235362. doi:
10.1371/journal.pone.0235362. [PMID: 32584895] - Hirokazu Konishi, Katsumi Miyauchi, Akira Onishi, Shunichi Suzuki, Daiichiro Fuchimoto, Jun Shitara, Hirohisa Endo, Hideki Wada, Shinichiro Doi, Ryo Naito, Manabu Ogita, Tomotaka Dohi, Takatoshi Kasai, Hiroyuki Daida. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
PloS one.
2020; 15(11):e0241195. doi:
10.1371/journal.pone.0241195. [PMID: 33201888] - Jean-Charles Fruchart, Raul D Santos. SPPARM alpha: the Lazarus effect.
Current opinion in lipidology.
2019 12; 30(6):419-427. doi:
10.1097/mol.0000000000000640. [PMID: 31577610] - Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideki Suganami, Shun Ishibashi. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
International journal of molecular sciences.
2019 Nov; 20(22):. doi:
10.3390/ijms20225537. [PMID: 31698825] - Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Narihito Yoshioka, Yukio Tanizawa, Hirotaka Watada, Hideki Suganami, Shun Ishibashi. Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
Diabetes, obesity & metabolism.
2019 07; 21(7):1737-1744. doi:
10.1111/dom.13686. [PMID: 30830727] - Jean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, Masanori Aikawa, Khalid Al Rasadi, Pierre Amarenco, Philip J Barter, Richard Ceska, Alberto Corsini, Jean-Pierre Després, Patrick Duriez, Robert H Eckel, Marat V Ezhov, Michel Farnier, Henry N Ginsberg, Michel P Hermans, Shun Ishibashi, Fredrik Karpe, Tatsuhiko Kodama, Wolfgang Koenig, Michel Krempf, Soo Lim, Alberto J Lorenzatti, Ruth McPherson, Jesus Millan Nuñez-Cortes, Børge G Nordestgaard, Hisao Ogawa, Chris J Packard, Jorge Plutzky, Carlos I Ponte-Negretti, Aruna Pradhan, Kausik K Ray, Željko Reiner, Paul M Ridker, Massimiliano Ruscica, Shaukat Sadikot, Hitoshi Shimano, Piyamitr Sritara, Jane K Stock, Ta-Chen Su, Andrey V Susekov, André Tartar, Marja-Riitta Taskinen, Alexander Tenenbaum, Lale S Tokgözoğlu, Brian Tomlinson, Anne Tybjærg-Hansen, Paul Valensi, Michal Vrablík, Walter Wahli, Gerald F Watts, Shizuya Yamashita, Koutaro Yokote, Alberto Zambon, Peter Libby. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Cardiovascular diabetology.
2019 06; 18(1):71. doi:
10.1186/s12933-019-0864-7. [PMID: 31164165] - Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Journal of atherosclerosis and thrombosis.
2019 May; 26(5):389-402. doi:
10.5551/jat.48918. [PMID: 30930344] - Satoshi Ida, Ryutaro Kaneko, Kazuya Murata. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
Cardiovascular diabetology.
2019 03; 18(1):38. doi:
10.1186/s12933-019-0845-x. [PMID: 30898163] - Koutaro Yokote, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Hideki Suganami, Shun Ishibashi, On Behalf Of The K-Study Group. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
International journal of molecular sciences.
2019 Feb; 20(3):. doi:
10.3390/ijms20030706. [PMID: 30736366] - Shin-Ichiro Ogawa, Yoshihiko Tsunenari, Hiroyuki Kawai, Hiroshi Yamazaki. Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys.
Biopharmaceutics & drug disposition.
2019 Jan; 40(1):12-17. doi:
10.1002/bdd.2165. [PMID: 30517973] - Haizhou Wang, Haiou Li, Yunjiao Zhou, Jing Liu, Fan Wang, Qiu Zhao. Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate.
Current pharmaceutical design.
2019; 25(44):4725-4734. doi:
10.2174/1381612825666191126102943. [PMID: 31769360] - Aruna D Pradhan, Nina P Paynter, Brendan M Everett, Robert J Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R Hiatt, Shun Ishibashi, Wolfgang Koenig, Børge G Nordestgaard, Jean-Charles Fruchart, Peter Libby, Paul M Ridker. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
American heart journal.
2018 12; 206(?):80-93. doi:
10.1016/j.ahj.2018.09.011. [PMID: 30342298] - Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Hideki Suganami, Shun Ishibashi. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
Journal of clinical lipidology.
2018 Sep; 12(5):1267-1279.e4. doi:
10.1016/j.jacl.2018.06.010. [PMID: 30077640] - Masaya Araki, Yoshimi Nakagawa, Asayo Oishi, Song-Iee Han, Yunong Wang, Kae Kumagai, Hiroshi Ohno, Yuhei Mizunoe, Hitoshi Iwasaki, Motohiro Sekiya, Takashi Matsuzaka, Hitoshi Shimano. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
International journal of molecular sciences.
2018 Jul; 19(7):. doi:
10.3390/ijms19072148. [PMID: 30041488] - Hidenori Arai, Shizuya Yamashita, Koutaro Yokote, Eiichi Araki, Hideki Suganami, Shun Ishibashi. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Journal of atherosclerosis and thrombosis.
2018 Jun; 25(6):521-538. doi:
10.5551/jat.44412. [PMID: 29628483] - Yuta Yamamoto, Kenta Takei, Sundaram Arulmozhiraja, Vladimir Sladek, Naoya Matsuo, Song-Iee Han, Takashi Matsuzaka, Motohiro Sekiya, Takaki Tokiwa, Mitsuo Shoji, Yasuteru Shigeta, Yoshimi Nakagawa, Hiroaki Tokiwa, Hitoshi Shimano. Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.
Biochemical and biophysical research communications.
2018 05; 499(2):239-245. doi:
10.1016/j.bbrc.2018.03.135. [PMID: 29567478] - Margherita Botta, Matteo Audano, Amirhossein Sahebkar, Cesare R Sirtori, Nico Mitro, Massimiliano Ruscica. PPAR Agonists and Metabolic Syndrome: An Established Role?.
International journal of molecular sciences.
2018 Apr; 19(4):. doi:
10.3390/ijms19041197. [PMID: 29662003] - Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Narihito Yoshioka, Yukio Tanizawa, Hirotaka Watada, Hideki Suganami, Shun Ishibashi. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Diabetes care.
2018 03; 41(3):538-546. doi:
10.2337/dc17-1589. [PMID: 29298800] - Hannah A Blair. Pemafibrate: First Global Approval.
Drugs.
2017 Oct; 77(16):1805-1810. doi:
10.1007/s40265-017-0818-x. [PMID: 28929345] - Yasushi Honda, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Koji Fujita, Masato Yoneda, Toshiaki Takizawa, Satoru Saito, Yoji Nagashima, Atsushi Nakajima. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Scientific reports.
2017 02; 7(?):42477. doi:
10.1038/srep42477. [PMID: 28195199] - Nathalie Hennuyer, Isabelle Duplan, Charlotte Paquet, Jonathan Vanhoutte, Eloise Woitrain, Véronique Touche, Sophie Colin, Emmanuelle Vallez, Sophie Lestavel, Philippe Lefebvre, Bart Staels. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Atherosclerosis.
2016 06; 249(?):200-8. doi:
10.1016/j.atherosclerosis.2016.03.003. [PMID: 27108950] - Ken Kitajima, Shin-Ichiro Miura, Yoshino Mastuo, Yoshinari Uehara, Keijiro Saku. Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation.
Atherosclerosis.
2009 Mar; 203(1):75-81. doi:
10.1016/j.atherosclerosis.2008.05.055. [PMID: 18606415] - Yukiyoshi Yamazaki, Shin-ichiro Ogawa, Kimiyuki Shibuya. Synthesis of highly deuterium-labeled (R)-K-13675, PPAR alpha agonist, for use as an internal standard for low-level quantification of drugs in plasma.
Bioorganic & medicinal chemistry.
2009 Mar; 17(5):1911-7. doi:
10.1016/j.bmc.2009.01.049. [PMID: 19217302] - Yukiyoshi Yamazaki, Kazutoyo Abe, Tsutomu Toma, Masahiro Nishikawa, Hidefumi Ozawa, Ayumu Okuda, Takaaki Araki, Soichi Oda, Keisuke Inoue, Kimiyuki Shibuya, Bart Staels, Jean-Charles Fruchart. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
Bioorganic & medicinal chemistry letters.
2007 Aug; 17(16):4689-93. doi:
10.1016/j.bmcl.2007.05.066. [PMID: 17553678]
